Evidence map›Paper›PMID 39355923›Full record

SynthesisCirculation2024

Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis.

Davor Vukadinović, Lucas Lauder, David E Kandzari, Deepak L Bhatt, Ajay J Kirtane, Elazer R Edelman, Roland E Schmieder, Michel Azizi, Michael Böhm, Felix Mahfoud

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Trial
  3. Trial
  4. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a commentary from the European Renal Best Practice (ERBP).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Article
  5. Review
  6. Blood pressure management for stroke patients beyond the JSH 2025 guidelines.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. The sympathetic nervous system in the pathophysiology of hypertension: Mechanistic insights and therapeutic implications.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  14. Review
  15. Overcoming variable response in renal denervation: Key strategies for reliable clinical implementation.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  16. Assessment of a "main renal artery + branches" ablation strategy for catheter-based circumferential ultrasonic renal denervation.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  17. Wireless soft implantable pressure sensors based on liquid metal with large-area mapping and adaptive implantation capabilities.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  18. Effect of renal denervation on the lipid profile in patients with or without coronary artery disease.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Davor VukadinovićKlinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Universität des Saarlandes, Homburg, Germany (D.V., L.L., M.B., F.M.).ORCID 0000-0002-7094-5961
Lucas LauderKlinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Universität des Saarlandes, Homburg, Germany (D.V., L.L., M.B., F.M.).ORCID 0000-0003-1434-9556
David E KandzariPiedmont Heart Institute, Atlanta, GA (D.E.K.).ORCID 0000-0002-0868-6655
Deepak L BhattMount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY (D.L.B.).ORCID 0000-0002-1278-6245
Ajay J KirtaneColumbia University Irving Medical Center/NewYork-Presbyterian Hospital and the Cardiovascular Research Foundation, New York, NY (A.J.K.).ORCID 0000-0003-0061-1058
Elazer R EdelmanInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge (E.R.E., F.M.).ORCID 0000-0002-7832-7156
Roland E SchmiederDepartment of Nephrology and Hypertension, University Hospital Erlangen, Friedrich Alexander University Erlangen/Nuremberg, Germany (R.E.S.).ORCID 0000-0003-2356-5883
Michel AziziUniversité Paris Cité, Paris, France (M.A.).ORCID 0000-0003-0597-8318
Michael BöhmKlinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Universität des Saarlandes, Homburg, Germany (D.V., L.L., M.B., F.M.).
Felix MahfoudKlinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Universität des Saarlandes, Homburg, Germany (D.V., L.L., M.B., F.M.).ORCID 0000-0002-4425-549X

Funding

Personalized lesion modification optimizes atherosclerosis interventionR01HL161069 · NHLBI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI EDELMAN, ELAZER R · 2022 to 2025
$2.8M
NHLBI NIH HHS R01 HL161069
6 · The paper itself

Abstract

backgroundSeveral sham-controlled trials have investigated the efficacy and safety of catheter-based renal denervation (RDN) with mixed outcomes. We aimed to perform a comprehensive meta-analysis of all randomized, sham-controlled trials investigating RDN with first- and second-generation devices in hypertension.

methodsWe searched MEDLINE and the Cochrane Library for eligible trials. Outcomes included both efficacy (24-hour and office systolic [SBP] and diastolic blood pressure [DBP]) and safety (all-cause death, vascular complication, renal artery stenosis >70%, hypertensive crisis) of RDN. We performed a study-level, pairwise, random-effects meta-analysis of the summary data.

resultsTen trials comprising 2478 patients with hypertension while being either off or on treatment were included. Compared with sham, RDN reduced 24-hour and office systolic blood pressure by 4.4 mm Hg (95% CI, 2.7 to 6.1;

conclusionsRDN safely reduces ambulatory and office systolic blood pressure/diastolic blood pressure versus a sham procedure in the presence and absence of antihypertensive medications.

Indexed as

HypertensionKidneyBlood PressureCatheter AblationHumansRandomized Controlled Trials as TopicRenal ArterySympathectomyTreatment Outcomearterial hypertensionmeta-analysisrenal denervation

Identifiers

PMID39355923
PMCPMC11560572

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.